In May 2005, preliminary trial results pronouncing the effectiveness of Herceptin (trastuzumab) for treatment of early-stage breast cancer were disseminated at a high-profile scientific meeting. Herceptin was subsequently approved for use in the public healthcare systems of Canada and the United Kingdom, although the differences between the two decision timelines were stark. The authors compared UK and Canadian newspaper coverage of the Herceptin story to assess how it may have been "hyped" in

more »

... ach country. They analyzed a diverse sample of newspapers and coded clippings for reporters' framing of the drug' s efficacy, costs and funding approval process. Canadian news coverage preceded formal publication of the trial results, while UK [e114]